Rational design of antibodies and development of a novel method for (1–3)-β-D glucan detection as an alternative to Limulus amebocyte lysate assay
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1322264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Chunlong Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Engineering Research Center, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China. Hauptthemen laut MEDLINE: beta-Glucans, Invasive Fungal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With advances in medicine, increasing medical interventions have increased the risk of invasive fungal disease development. (1-3)-β-D glucan (BDG) is a common fungal biomarker in serological tests. However, the scarcity of Limulus resources for BDG detection poses a challenge. This study addresses the need for an alternative to Limulus amebocyte lysate by using BDG mutant antibody for chemiluminescence detection. The wild-type BDG antibody was obtained by immunizing rabbits. An optimal V52 H I/N34 L Y mutant antibody, which has increased 3.7-fold of the testing efficiency compared to the wild-type antibody, was first achieved by mutating “hot-spot” residues that contribute to strong non-covalent bonds, as determined by alanine scanning and molecular dynamics simulation. The mutant was then applied to develop the magnetic particle chemiluminescence method. 574 clinical samples were tested using the developed method, with a cutoff value of 95 pg/mL set by Limulus amebocyte lysate. The receiver operating characteristic curve demonstrated an area under the curve of 0.905 (95% CI: 0.880–0.929). Chemiluminescence detected an antigen concentration of 89.98 pg/mL, exhibiting a sensitivity of 83.33% and specificity of 89.76%. In conclusion, the results showed a good agreement with Limulus amebocyte lysate and demonstrated the feasibility of using BDG mutant antibodies for invasive fungal disease diagnosis. The new method based on chemiluminescence for detecting BDG could shorten the sample-to-result time to approximately 30 min, rescue Limulus from being endangered and is resource efficient in terms of equipment and the non-use of a skilled technician.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical Engineering Research Center, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.
- R&D Department, Dynamiker Biotechnology (Tianjin) Co., Ltd, Tianjin, China.
- Tianjin Key Laboratory of Membrane Science and Desalination Technology, Tianjin University, Tianjin, China.
- State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin, China.
- Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China.
Zitieren
APA
Liu, C., Zhang, L., Zhang, J., Wang, M., You, S., Su, R., & Qi, W. (2024). Rational design of antibodies and development of a novel method for (1–3)-β-D glucan detection as an alternative to Limulus amebocyte lysate assay. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1322264
Vancouver
Liu C, Zhang L, Zhang J, Wang M, You S, Su R, et al. Rational design of antibodies and development of a novel method for (1–3)-β-D glucan detection as an alternative to Limulus amebocyte lysate assay. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1322264
BibTeX
@article{Liu2024,
author = {Liu, Chunlong and Zhang, Lin and Zhang, Jiaxing and Wang, Mengfan and You, Shengping and Su, Rongxin and Qi, Wei},
title = {Rational design of antibodies and development of a novel method for (1–3)-β-D glucan detection as an alternative to Limulus amebocyte lysate assay},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1322264}
}
EUVIMED